Monitoring and Characteristics of Major Mastitis Pathogens from Bulk Tank Milk in Korea

Mun-Jo Yun 1,2,*, Sungyun Yoon 3,1 and Young Ju Lee 1,*

1 College of Veterinary Medicine & Zoonoses Research Institute, Kyungpook National University, Daegu 41566, Korea; yun200297@naver.com (M.-J.Y.); sungyoon@knu.ac.kr (S.Y.)
2 Gyeongsangbuk-do Provincial Government Office, Andong 36759, Korea
* Correspondence: youngju@knu.ac.kr; Tel.: +82-53-950-7793
† These authors contributed equally to this work.

Received: 02 August 2020; Accepted: 31 August 2020; Published: 2 September 2020

Simple Summary: The monitoring of milk quality and the presence of major mastitis pathogens is an important part of milk quality assurance program. Bulk tank milk has been used in many countries to identify multiple milk quality problems and mastitis pathogens that might exist in a dairy herd. This study aimed to compare the presence of mastitis pathogens and the antimicrobial resistance of the isolates from bulk tank milk by dairy companies. The results showed that the prevalence of mastitis pathogens and the antimicrobial resistance of the isolates were significantly different among factories, and support the development of strong monitoring and prevention programs in dairy operations.

Abstract: In many countries, bulk tank milk (BTM) has been used for examining milk and analyzed as an important part of milk quality assurance programs. The objectives of this study were to investigate milk quality and the presence of major mastitis pathogens in BTM, and to compare the characteristics of BTM by dairy factory or company. A total of 1588 batches of BTM samples were collected from 396 dairy farms of seven dairy factories owned by four companies in Korea. The means of individual bacterial counts (IBC) and somatic cell count (SCC) were 3.7 × 10^4 cells/mL and 1.1 × 10^6 cells/mL, respectively, and no significant differences among dairy factories were observed. The most common pathogen was Staphylococcus spp. (60.1%), followed by E. faecalis (53.8%), E. coli (37.6%) and Streptococcus spp. (22.5%). Enterococcus spp. showed the highest resistance to tetracyclines (51.1% to 73.9%) and macrolides (46.5%). S. aureus and coagulase-negative staphylococci (CNS) showed the highest resistance to penicillin (28.4% and 40.2%, respectively), and three (3.2%) S. aureus and seven (3.3%) CNS were also methicillin-resistant. These data show the diverse prevalence and characteristics of major mastitis pathogens among factories, and support the development of strong monitoring and prevention programs of mastitis pathogens by commercial dairy operations.

Keywords: bulk tank milk; mastitis pathogen; antimicrobial resistance; somatic cell count

1. Introduction

Bulk tank milk (BTM) has been used for identifying multiple milk quality problems and mastitis pathogens that might exist in a dairy herd. It is analyzed as an important part of milk quality assurance programs in many countries [1–4]. Microbiological screening of all cows in a herd can be laborious and expensive, so performing tests using BTM is convenient and economical [5]. The isolation of mastitis pathogens from BTM indicates that contamination or intramammary infection is present in one or more cows on the farm [6], so monitoring BTM samples is useful in controlling
mastitis on dairy farms because early detection of the causative pathogens is the most effective way to prevent disease and guide treatment [7].

In most countries, the bacterial quality of BTM is monitored by individual bacterial counts (IBC) and somatic cell count (SCC) [8,9]. In particular, the majority of somatic cells are leukocytes, which increase in milk, usually as an immune response to mastitis. A threshold SCC of 2 × 10⁶ cells/mL would determine the financial penalty of milk, and an SCC of more than 5 × 10⁶ cells/mL makes milk deemed unfit for human consumption in Korea [10]. Not only the contagious pathogens, such as S. aureus and Streptococcus spp., which can be transferred from cow to cow, but also environmental pathogens such as E. coli, Enterococcus spp. and coagulase-negative staphylococci (CNS), which are considered opportunistic pathogens responsible for subclinical mastitis, can be spread to other cows through a contaminated environment in the barn and the milking process [11].

Antimicrobial therapy is common in Korea, which is one of the key components for the control of infectious mastitis, so the emergence of the antimicrobial resistance in major mastitis pathogens such as methicillin-resistant S. aureus (MRSA) has been reported [12], and is a public health concern [13]. The dairy farm environment has also been reported as a reservoir for the distribution of antimicrobial resistance [14]. The purpose of this study was to investigate the milk quality and the presence of contagious and environmental mastitis pathogens, such as E. coli, Enterococcus spp., S. aureus, CNS and Streptococcus spp. in BTM, which consists of raw milk from cows of dairy farms where mastitis has not been detected, and to compare the characteristics of BTM by dairy factory or company. To our knowledge, there are no reports on monitoring and comparing the quality of BTM among dairy factories in Korea.

2. Materials and Methods

2.1. Collection of Samples

A total of 1588 batches of BTM were collected from 396 dairy farms of seven dairy factories operated by four companies in Korea. Milk samples, 50 mL each, were aseptically collected two times in the summer and winter season during the study period (July–December 2019) and sent to the laboratory under 4 °C conditions. All samples were then individually tested for IBC, SCC and identification of bacterial isolates within 24 h.

2.2. IBC and SCC

All batches of BTM were analyzed for IBC and SCC using BactoScan FC (Foss Electric, Hillerod, Denmark) and Milkoscan CombiFoss 6000 (Foss Electric, Oceanside, CA, USA), respectively.

2.3. Bacterial Identification

The isolation and identification of mastitis pathogens were performed following the standard microbiological protocols published by the Ministry of Food and Drug Safety (2018) [15]. Among the many mastitis pathogens, E. coli, Enterococcus spp., Staphylococcus spp. and Streptococcus spp. were investigated in this study. Briefly, one mL of each milk sample was aerobically cultured in 9 mL of mEC (Merck, Darmstadt, Germany), tryptic soy broth with 6% NaCl (BD Biosciences, Sparks, MD) and Todd Hewitt broth (BD Biosciences) for E. coli, Staphylococcus spp. and Streptococcus spp., respectively. After incubation at 37 °C for 24 h, each medium was streaked onto MacConkey agar (BD Biosciences), Baird-Parker agar (BD Biosciences) and 5% sheep blood agar (KOMED, Seoul, Korea), respectively. For isolation of Enterococcus spp., one mL of the milk sample was cultured in 9 mL of buffered peptone water (BPW; BD Biosciences). Then, pre-enriched BPW was mixed with Enterococcusol broth (BD Biosciences) at a 1:10 ratio. After incubation at 37 °C for 18–24 h, each medium was streaked onto Enterococcusol agar (BD Biosciences). Suspected colonies were transferred to each selective medium for bacterial identification. Confirmation of E. coli, E. faecalis, E. faecium, S. aureus and Streptococcus spp. was performed using PCR with specific primers (Table 1). Classification of CNS spp. and Streptococcus spp. was performed by MALDI-TOF mass spectrometry (Biomerieux, Marcy-l’Étoile, France) based on the protein expression profiles using VITEK MS system.
(Biomerieux). If two isolates of the same origin showed the same antimicrobial susceptibility patterns, only one isolate was randomly chosen and included in this study.

Table 1. PCR primers used in this study.

| Microorganism | Target Gene | Primer | Sequence (5'-3') | Amplicon Size (bp) | Annealing Temperature (°C) | References |
|---------------|-------------|--------|------------------|-------------------|---------------------------|------------|
| E. coli       | malB        | malBF  | TCGCCACACGCTGACCTGACCA  | 585               | 55                        | [16]       |
| E. faecalis   | ddl1        | ddl1F  | TGTGTGTGGCCGACGAAGT   | 941               | 54                        | [17]       |
| E. faecium    | ddl2        | ddl2F  | ATGGGACCCAAGTGGACAGA  | 550               | 54                        | [18]       |
| S. aureus     | nuc         | NucF   | GCGATTGATGCTAGCCGTT   | 279                | 55                        | [19]       |
| Streptococcus | 16S-23S     | SU-F2  | AGCCGCCTAAGGTTGATG    | 220-230            | 60                        | [22]       |

2.4. Antimicrobial Susceptibility Testing

Based on the Clinical and Laboratory Standards Institute guidelines (CLSI, 2019) [20], all pathogens were investigated for antimicrobial resistance using the disc diffusion test with the following discs (BD Biosciences): amikacin (A, 30 μg), ampicillin (AM, 10 μg), amoxicillin-clavulanate (AMC, 20 μg), chloramphenicol (C, 30 μg), ceftazidime (CAZ, 30 μg), clindamycin (CC, 2 μg), cefadroxil (CDX, 30 μg), cefalothin (CF, 30 μg), ciprofloxacin (CIP, 5 μg), colistin (CL, 10 μg), cefotaxime (CTX, 30 μg), cefuroxime (CMX, 30 μg), cefazoline (CZ, 30 μg), doxycycline (DOX, 30 μg), erythromycin (E, 15 μg), nitrofurantoin (F/M, 300 μg), cefepime (FEP, 30 μg), cefotaxin (FOX, 30 μg), gentamicin (G, 10 μg), imipenem (IPM, 10 μg), kanamycin (K, 30 μg), levofloxacin (LVX, 5 μg), nalidixic acid (Na, 30 μg), norfloxacin (NOR, 10 μg), ofloxacin (OFX, 5 μg), oxacillin (OX, 1 μg), penicillin (P, 10 units), rifampin (RA, 5 μg), trimethoprim/sulfamethoxazole (SXT, 1.25 μg), tetracycline (TE, 30 μg), teicoplanin (TEC, 30 μg) and vancomycin (VA, 30 μg). Methicillin resistance in S. aureus and CNS isolates was determined by the results of the cefoxitin disk diffusion test as recommended by CLSI (2019) [20] and Pourmand et al. (2014) [21]. E. coli ATCC 25922, E. faecalis ATCC 29,212 and S. aureus ATCC 29,213 were used as the quality controls. Multidrug resistance (MDR) was defined as acquired resistance to at least one agent in three or more antimicrobial classes [22].

2.5. Statistical Analysis

Statistical analyses were performed using SPSS 25 (IBM Corp., Armonk, NY, USA). The analysis of the differences of the means of IBC and SCC samples collected from each dairy factory were carried out by a logarithmic transformation of values with log base 10 as reported by Lopes Júnior (2012) and conducted by one-way ANOVAs [8]. If a significant difference (p < 0.05) in the prevalence of pathogens among factories was confirmed by the Chi-square test, post-hoc analyses using the Bonferroni correction were performed for multiple tests in subsequent analyses of the seven dairy factories, as previously reported [23].

3. Results

3.1. Comparison of IBC and SCC

Comparisons of IBC and SCC in BTM from 396 farms of seven dairy factories are shown in Table 2. Means of \( \log_{10} \text{IBC} \) and \( \log_{10} \text{SCC} \) were 4.38 ± 0.53–4.57 ± 0.41 and 4.94 ± 0.39–5.10 ± 0.46, respectively. The means of IBC from four of the seven factories were greater than 3.0 × 10^4 cells/mL.
Table 2. Distribution of individual bacterial count (IBC) and somatic cell count (SCC) in bulk tank milk samples from dairy factories.

| Company | Dairy Factory | Number of Bulk Tank Milk Samples | Log10IBC | Geometric Mean of IBC (cells/mL) | log10SCC | Geometric Mean of SCC (cells/mL) |
|---------|---------------|---------------------------------|----------|---------------------------------|----------|---------------------------------|
|         |               |                                 | Mean b   | SD c                             | CI d     | Mean e                          | SD c | CI d |
| A       | A-1           | 200                             | 4.38     | 0.53                            | 4.23–4.53 | 24,039                          | 5.02 | 0.48 | 4.88–5.16 | 105,024    |
| A       | A-2           | 224                             | 4.48     | 0.66                            | 4.30–4.65 | 30,135                          | 5.06 | 0.64 | 4.89–5.23 | 115,320    |
| B       | B-1           | 480                             | 4.57     | 0.41                            | 4.49–4.64 | 36,939                          | 5.10 | 0.46 | 5.01–5.18 | 124,517    |
| C       | C-1           | 188                             | 4.51     | 0.37                            | 4.40–4.62 | 32,598                          | 5.01 | 0.40 | 4.89–5.13 | 102,245    |
| D       | D-1           | 232                             | 4.43     | 0.37                            | 4.33–4.53 | 26,955                          | 4.94 | 0.39 | 4.83–5.04 | 86,570     |
| D       | D-2           | 132                             | 4.40     | 0.44                            | 4.25–4.56 | 25,405                          | 4.97 | 0.43 | 4.82–5.12 | 92,614     |
| D       | D-3           | 128                             | 4.43     | 0.53                            | 4.24–4.62 | 26,651                          | 4.95 | 0.48 | 4.78–5.13 | 89,975     |
| Total   |               | 1588                            | 4.48     | 0.48                            | 4.43–4.53 | 30,197                          | 5.03 | 0.48 | 4.98–5.07 | 107,261    |

*The bulk tank milk samples were collected two times, summer and winter (July to December 2019) from 396 dairy farms of seven factories of four dairy companies. b Mean of log10IBC were not significantly different among factories (p = 0.219); c SD, standard deviation; d CI, confidence interval (95%); e Mean of log10SCC were not significantly different among factories (p = 0.418).

3.2. Distribution of Major Mastitis Pathogens

The distributions of pathogens in BTM are shown in Table 3. Although the most common pathogens were *Staphylococcus* spp. (238 farms, 60.1%), the prevalence of CNS (164 farms, 41.4%) was higher than that of *S. aureus* (95 farms, 24.0%). The prevalence of *E. faecalis, E. coli* and *Streptococcus* spp. was 53.8%, 37.6% and 22.5%, respectively. In the distribution of pathogens among dairy factories, *E. coli* and *S. aureus* were not detected from factories A-1 and A-2 and factory B-1. Moreover, the prevalence of *E. coli, Enterococcus* spp. and *S. aureus* was significantly different among factories by application of the Bonferroni correction. In particular, the prevalence of *E. coli* from factories D-2 and D-3 and *E. faecalis* from factory D-3 was significantly higher than in the other factories, but factory A-2 had a significantly higher prevalence of *S. aureus* than other factories had.
Table 3. Species and distribution of pathogens isolated from 396 dairy farms among seven dairy factories.

| Genus.               | Species                     | A-1 (n = 50) | A-2 (n = 56) | B-1 (n = 120) | C-1 (n = 47) | D-1 (n = 58) | D-2 (n = 33) | D-3 (n = 32) | Total (%) (n = 396) |
|----------------------|-----------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|----------------------|
| Escherichia coli     |                             | 0 (0.0) *    | 0 (0.0) *    | 37 (30.8) *  | 28 (59.6) *  | 29 (50.0) *  | 26 (78.8) *  | 29 (90.6) *  | 149 (37.6)          |
| Enterococcus spp.    |                             | 20 (40.0) *  | 19 (33.9) *  | 69 (57.5) *  | 30 (63.8) *  | 38 (65.5) *  | 23 (69.7) *  | 32 (100.0) * | 231 (58.3)          |
|                      | Enterococcus faecalis       | 18 (36.0) *  | 19 (33.9) *  | 64 (53.3) *  | 25 (53.2) *  | 35 (60.3) *  | 21 (63.6) *  | 31 (96.9) *  | 213 (53.8)          |
|                      | Enterococcus faecium        | 2 (4.0)      | 2 (3.6)      | 6 (5.0)      | 11 (23.4) *  | 6 (10.3)     | 2 (6.1)      | 1 (3.1)      | 30 (7.6)            |
| Staphylococcus spp.  |                             | 48 (96.0) *  | 52 (92.9) *  | 40 (33.3) *  | 24 (51.1)    | 48 (82.8) *  | 18 (54.5)    | 8 (25.0)     | 238 (60.1)          |
|                      | Staphylococcus aureus       | 19 (38.0)    | 52 (92.9) *  | 0 (0.0) *    | 3 (6.4) *    | 5 (8.6)      | 13 (39.4)    | 3 (9.4)      | 95 (24.0)           |
| Coagulase-negative   | Staphylococcus                | 37 (74.0) *  | 8 (14.3) *   | 40 (33.3)    | 22 (46.8)    | 44 (73.9) *  | 8 (24.2)     | 5 (15.6)     | 164 (41.4)          |
| Staphylococcus       | chromogenes                 | 35 (70.0) *  | 6 (10.7)     | 3 (2.5) *    | 2 (4.3)      | 12 (20.7)    | 4 (12.1)     | 1 (3.1)      | 63 (15.9)           |
| Staphylococcus       | saprophyticus               | 0 (0.0)      | 1 (1.8)      | 17 (14.2)    | 12 (25.5) *  | 14 (24.1) *  | 1 (3.0)      | 0 (0.0)      | 45 (11.4)           |
| Staphylococcus       | xylosus                     | 1 (2.0)      | 1 (1.8)      | 6 (5.0)      | 3 (6.4)      | 6 (10.3)     | 0 (0.0)      | 0 (0.0)      | 17 (4.3)            |
| Staphylococcus       | haemolyticus                | 0 (0.0)      | 0 (0.0)      | 5 (4.2)      | 1 (2.1)      | 4 (6.9)      | 1 (3.0)      | 0 (0.0)      | 11 (2.8)            |
| Staphylococcus       | simulans                    | 1 (2.0)      | 0 (0.0)      | 0 (0.0)      | 1 (1.7)      | 2 (6.1)      | 2 (6.3)      | 6 (1.5)      |                     |
| Staphylococcus       | sciuri                      | 0 (0.0)      | 0 (0.0)      | 2 (1.7)      | 2 (4.3)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 5 (1.3)            |
| Staphylococcus       | capitis                     | 0 (0.0)      | 0 (0.0)      | 1 (0.8)      | 0 (0.0)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 3 (0.8)            |
| Staphylococcus       | cohnii                      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (2.1)      | 0 (0.0)      | 0 (0.0)      | 1 (3.1)      | 2 (0.5)            |
| Staphylococcus       | epidermidis                 | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (2.1)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 2 (0.5)            |
| Staphylococcus       | equorum                     | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (2.1)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 2 (0.5)            |
| Staphylococcus       | gallinarum                  | 0 (0.0)      | 0 (0.0)      | 1 (0.8)      | 0 (0.0)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 2 (0.5)            |
| Staphylococcus       | succinus                    | 0 (0.0)      | 0 (0.0)      | 2 (1.7)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 2 (0.5)            |
| Staphylococcus       | hyicus                      | 0 (0.0)      | 0 (0.0)      | 1 (0.8)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (3.1)      | 2 (0.5)            |
| Staphylococcus       | arletae                     | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (0.3)            |
| Staphylococcus       | lentus                      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (1.7)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (0.3)            |
| Streptococcus spp.   |                             | 6 (12.0)     | 9 (16.1)     | 27 (22.5)    | 10 (21.3)    | 16 (27.6)    | 18 (54.5)    | 3 (9.4)      | 89 (22.5)           |
| Streptococcus        | bovis                       | 0 (0.0)      | 0 (0.0)      | 14 (11.7)    | 0 (0.0)      | 3 (5.2)      | 8 (24.2) *   | 0 (0.0)      | 25 (6.3)            |
| Streptococcus        | uberis                      | 1 (2.0)      | 9 (16.1)     | 3 (2.5)      | 3 (6.4)      | 1 (1.7)      | 0 (0.0)      | 2 (6.3)      | 19 (4.8)            |
| Streptococcus        | oralis                      | 3 (6.0)      | 0 (0.0)      | 0 (0.0)      | 2 (4.3)      | 4 (6.9)      | 6 (18.2) *   | 1 (3.1)      | 16 (4.0)            |
| Streptococcus        | infantarius                 | 0 (0.0)      | 0 (0.0)      | 4 (3.3)      | 0 (0.0)      | 0 (0.0)      | 3 (9.1) *    | 0 (0.0)      | 7 (1.8)             |
| Streptococcus        | agalactiae                  | 1 (2.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (0.3)             |
| Streptococcus        | intermedius                 | 0 (0.0)      | 0 (0.0)      | 1 (0.8)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (0.3)             |
| Unidentified         |                             | 1 (2.0)      | 0 (0.0)      | 5 (4.2)      | 5 (10.6)     | 8 (13.8) *   | 1 (3.0)      | 0 (0.0)      | 20 (5.1)            |

*a Seven factories were operated by four dairy companies, and the same capital letter indicates factories operated by the same company. * The asterisk indicates that prevalence of the pathogen isolated from the factory was significantly different than that of other factories using the Bonferroni correction.
3.3. Antimicrobial Resistance

Antimicrobial resistance patterns of 918 pathogens isolated from BTM are shown in Table 4. While *E. coli* had the lowest resistance, from 0% to 13.1%, to all antimicrobials tested, *Enterococcus* spp. had the highest resistance to tetracyclines (51.1% to 73.9%) and macrolides (46.5%). *S. aureus* and CNS showed the highest resistance to penicillin (28.4% and 40.2%, respectively), and three (3.2%) *S. aureus* and seven (3.3%) CNS also showed methicillin resistance. *Streptococcus* spp. had the highest resistance to tetracycline (49.5%), followed by clindamycin (35.5%) and cefotaxime (24.7%).

Distribution of MDR pathogens is shown in Table 5. The highest prevalence of MDR was found in *Streptococcus* spp. (29.0%), followed by *Enterococcus* spp. (24.3%), CNS (16.4%) and *E. coli* (13.5%). The prevalence of MDR was lowest in *S. aureus* (2.1%). MDR to six antimicrobial classes was found in two *E. coli*, one CNS and one *S. aureus*, which were the isolates with an intermediate prevalence of MDR.

### Table 4. Antimicrobial resistance in 918 pathogens isolated from bulk tank milk.

| Antibiotic (Abbreviation) | E. coli (n = 183) | Enterococcus spp. (n = 333) | S. aureus (n = 95) | CNS (n = 214) | Streptococcus spp. (n = 93) |
|---------------------------|------------------|----------------------------|--------------------|--------------|-----------------------------|
| **β-Lactams**             |                  |                            |                    |              |                             |
| Penicillin (P)            | N/A              | 5 (1.5)                    | 27 (28.4)          | 86 (40.2)    | N/A                         |
| Ampicillin (AM)           | 24 (13.1)        | 2 (0.6)                    | 3 (3.2)            | 19 (8.9)     | N/A                         |
| Amoxicillin/clavulanate (AMC) | 5 (2.7)       | N/A                        | 2 (2.1)            | 12 (5.6)     | N/A                         |
| Oxacillin (OX)            | N/A              | N/A                        | 3 (3.2)            | 14 (6.5)     | N/A                         |
| Methicillin (MET)         | N/A              | N/A                        | 3 (3.2)            | 7 (3.3)      | N/A                         |
| **Cepham**                |                  |                            |                    |              |                             |
| Cefazolin (CZ)            | 9 (4.9)          | N/A                        | 3 (3.2)            | 3 (1.4)      | N/A                         |
| Cefadroxil (CDX)          | 5 (2.7)          | N/A                        | N/A                | N/A          | N/A                         |
| Cephalexin (CF)           | 25 (14)          | N/A                        | 1 (1.1)            | 2 (0.9)      | N/A                         |
| Cefuroxime (CMX)          | 3 (1.6)          | N/A                        | 1 (1.1)            | 3 (1.4)      | N/A                         |
| Cefoxitin (FOX)           | 3 (1.6)          | N/A                        | 3 (3.2)            | 7 (3.3)      | N/A                         |
| Cefazidime (CAZ)          | 5 (2.7)          | N/A                        | 1 (1.1)            | 2 (0.9)      | N/A                         |
| Cefotaxime (CTX)          | 3 (1.6)          | N/A                        | 1 (1.1)            | 3 (1.4)      | 23 (24.7)                   |
| Cefepime (FEP)            | 3 (1.6)          | N/A                        | 1 (1.1)            | 3 (1.4)      | 21 (22.6)                   |
| **Glycopeptides**         |                  |                            |                    |              |                             |
| Vancomycin (VA)           | N/A              | 2 (0.6)                    | 0 (0.0)            | 0 (0.0)      | N/A                         |
| Teicoplanin (TEC)         | N/A              | N/A                        | 0 (0.0)            | 1 (0.5)      | N/A                         |
| Imipenem (IPM)            | 0 (0.0)          | N/A                        | N/A                | N/A          | N/A                         |
| **Aminoglycosides**       |                  |                            |                    |              |                             |
| Gentamicin (G)            | 19 (10)          | N/A                        | 1 (1.1)            | 3 (1.4)      | N/A                         |
| Amikacin (A)              | 0 (0.0)          | N/A                        | 0 (0.0)            | 0 (0.0)      | N/A                         |
| Kanamycin (K)             | 4 (2.2)          | N/A                        | 2 (2.1)            | 12 (5.6)     | N/A                         |
| **Macrolides**            |                  |                            |                    |              |                             |
| Erythromycin (E)          | N/A              | 155 (46.5)                 | 2 (2.1)            | 13 (6.1)     | 17 (18.3)                   |
| **Tetracyclines**         |                  |                            |                    |              |                             |
| Tetracycline (TE)         | 26 (14.2)        | 246 (73.9)                 | 2 (2.1)            | 65 (30.4)    | 46 (49.5)                   |
| Doxycycline (DOX)         | 9 (4.9)          | 170 (51.1)                 | 0 (0.0)            | 12 (5.6)     | N/A                         |
| **Quinolones**            |                  |                            |                    |              |                             |
| Nalidixic acid (Na)       | 2 (1.1)          | N/A                        | N/A                | N/A          | N/A                         |
| Fluoroquinolones          |                  |                            |                    |              |                             |
| Ciprofloxacin (CIP)       | 2 (1.1)          | 13 (3.9)                   | 1 (1.1)            | 1 (0.5)      | N/A                         |
| Levofloxacin (LVX)        | N/A              | 5 (1.5)                    | 1 (1.1)            | 1 (0.5)      | 1 (1.1)                     |
| Norfloxacin (NOR)         | N/A              | 5 (1.5)                    | 2 (2.1)            | 1 (0.5)      | N/A                         |
| Ofloxacin (OFX)           | N/A              | N/A                        | 1 (1.1)            | 1 (0.5)      | 2 (2.2)                     |
| **Nitrofurantoinos**      |                  |                            |                    |              |                             |
| Nitrofurantoin (F/M)      | N/A              | 0 (0.0)                    | 0 (0.0)            | 0 (0.0)      | N/A                         |
| **Lincosamides**          |                  |                            |                    |              |                             |
| Clindamycin (CC)          | N/A              | N/A                        | 1 (1.1)            | 8 (3.7)      | 33 (35.5)                   |
| **Folate pathway inhibitors** |                  |                            |                    |              |                             |
| Trimethoprim/sulfamethoxazole (SXT) | 7 (3.8) | N/A                        | 1 (1.1)            | 1 (0.5)      | 0 (0.0)                     |
| **Phenicols**             |                  |                            |                    |              |                             |
| Chloramphenicol (C)       | 11 (6.0)         | 87 (26.1)                  | 2 (2.1)            | 45 (21.0)    | 21 (22.6)                   |
4. Discussion

The IBC and SCC, which are used as general indicators of milk safety, did not show significant differences among factories ($p = 0.219$ and $p = 0.418$, respectively), which can be influenced by cow health, environment, milking procedures and equipment sanitation [24]. In Korea, most of the milk products are produced by five large dairy companies, which account for 84% of the total sales of dairy products in Korea [25]. They control and operate in all phases of the dairy production system [26]. Additionally, most dairy farms consist of herds living in confined space, resulting in a higher chance of contamination by environmental pathogens on teats of cows, as reported by Goldberg et al. (1992) [27]. In this study, the means of IBC of BTM samples from seven factories originating from four dairy companies ranged from $2.4 \times 10^4$ to $3.7 \times 10^4$ cells/mL. Although hygiene management and cow health have been continuously prioritized and financial penalties have been applied when the level of IBC is over $3.0 \times 10^4$ cells/mL, the means of IBC from four out of seven factories were still over $3.0 \times 10^4$ cells/mL. IBC gives an estimate of the total number of viable aerobic bacteria present in raw milk, and can be controlled by the consistent application of proper milking practices, udder hygiene and mastitis prevention [28]. A high level of IBC suggests that bacteria are entering the milk from a variety of possible sources. The most frequent cause is poor cleaning and cooling techniques of milking systems and milk residues on equipment surfaces, which provide nutrients for growth and multiplication of bacteria that contaminate subsequent milking [2]. Thus, dairy farms should improve control practices to reduce bacterial infection in milking processes, as previously reported [29].

The means of SCC of seven factories showed a relatively low level ($8.6 \times 10^4$–$1.2 \times 10^5$ cells/mL) compared to the established standard for financial penalties ($2.0 \times 10^5$ cells/mL). Additionally, the SCC of BTM samples had a lower level than that of raw milk samples in 2007 ($2.4 \times 10^5$ cells/mL) in Korea [30]. Although the lower SCC in BTM than the raw milk samples may be attributed to the dilution effect of milk masking a high SCC of individual cows [31], the BTM tested in this study may have consisted of raw milk from cows of dairy farms without clinical mastitis.

Although there were no significant differences in IBC and SCC among factories, there were significant differences in the prevalence of major mastitis pathogens, such as S. aureus, which might be caused by a relatively low level of pathogens in BTM, as previously reported by Fenlon et al. (1995) and Koop et al. (2010) [32,33]. In this study, the prevalence of E. faecalis and E. coli was 53.8% and 37.6%, respectively, and the prevalence in factories of D company, in particular, was significantly higher, although E. coli were not detected at all in the factories of A company. E. faecalis and E. coli

| Antimicrobial Classes | No. of Isolates (%) |
|-----------------------|---------------------|
| E. coli (n = 183)     | Enterococcus spp. (n = 333) | S. aureus (n = 95) | CNS * (n = 214) | Streptococcus spp. (n = 93) |
| 0                    | 119 (65.0)           | 39 (11.7)         | 65 (68.4)       | 76 (35.5)                 | 37 (39.8)             |
| 1                    | 36 (19.7)            | 102 (30.6)        | 23 (24.2)       | 64 (29.9)                 | 20 (21.5)             |
| 2                    | 12 (6.6)             | 111 (33.3)        | 5 (5.3)         | 39 (18.2)                 | 9 (9.7)               |
| 3                    | 11 (6.0)             | 72 (21.6)         | 1 (1.1)         | 19 (8.9)                  | 10 (10.8)             |
| 4                    | 2 (1.1)              | 8 (2.4)           | 0 (0.0)         | 10 (4.7)                  | 11 (11.8)             |
| 5                    | 1 (0.5)              | 1 (0.3)           | 0 (0.0)         | 5 (2.3)                   | 6 (6.5)               |
| 6                    | 2 (1.1)              | 0 (0.0)           | 1 (1.1)         | 1 (0.5)                   | 0 (0.0)               |
| No. (%) of MDR †     | 16 (8.7)             | 81 (24.3)         | 2 (2.1)         | 35 (16.4)                 | 27 (29.0)             |

* CNS, coagulase-negative Staphylococcus spp. † Multidrug resistance was defined as the acquired resistance to at least one agent in three or more antimicrobial classes.
are considered to indicate fecal contamination, produced under poor hygienic conditions [29]. The results in factories, including company D, may reflect poor management of fecal contamination, the most common source of pathogens in BTM [29]. Moreover, the prevalence of S. aureus was also significantly different among factories, and the A-2 factory of A company had a significantly higher prevalence than other factories. Although the samples from factory A-2 also showed low SCC, continuous monitoring of SCC is required, because S. aureus can lead to recurrent infection and shed in a cyclical way from mammary glands, which can result in clinical mastitis [34].

In this study, the prevalence of CNS and Streptococcus spp. was 41.4% and 22.5%, respectively. The presence of these pathogens does not necessarily induce inflammation [35], but it should be also monitored and controlled, because they are opportunistic pathogens that have the potential to be hazardous [7], causing clinical signs in a susceptible host [36].

Although the samples tested in this study consisted of raw milk from cows without clinical mastitis, the highest prevalence of antimicrobial resistance was found in Enterococcus spp. (88.2%), followed by CNS (64.5%), Streptococcus spp. (60.2%), E. coli (40.0%) and S. aureus (31.6%). In particular, antimicrobial resistance to tetracycline was relatively widespread in Enterococcus spp. (73.9%) and Streptococcus spp. (49.5%), as previous studies in Korea have shown [37,38]. Additionally, the resistance to penicillin was also high in S. aureus (28.4%) and CNS (40.2%), consistent with previous studies [37–39]. The prevalence of resistance to penicillin and tetracycline may be associated with the heavy use of these antimicrobials in the food animals, because these antibiotics have been reported to be the most consumed antimicrobials in Korea [40].

Cefoxitin resistance, which is considered as methicillin resistance in the CLSI (2019) guidelines, was found in three S. aureus and seven CNS [21]. MRSA and methicillin-resistant CNS are problematic, not only in the dairy industry but also in public health generally, because they cause resistant Staphylococcus spp. infections in humans [21,41]. Notably, two vancomycin-resistant isolates were also found in this study, which is concerning because of the limited therapeutic choices beyond vancomycin for treating infections with these organisms [42]. Therefore, further investigations on the risks to personnel on dairy farms should be conducted.

In addition, Streptococcus spp. was highly resistant to clindamycin (35.5%) and this percentage was slightly higher than in reports from China (28.7%) and Argentina (25.5%) [13,43]. Resistance to chloramphenicol was also found in all mastitis pathogens in this study (2.1–26.1%), as other studies in Korea have reported [38,44]. However, clindamycin has not been approved for use in cattle, and chloramphenicol has been withdrawn from food animal use in Korea since 1992 [45]. Phenicol antimicrobials, such as chloramphenicol and florfenicol, and lincosamide antimicrobials, such as clindamycin, are potent inhibitors of bacterial protein biosynthesis [46]. Although chloramphenicol and clindamycin have not been used in veterinary medicine, florfenicol has been widely used for veterinary medicine in Korea [47]. Resistance to phenicols and lincosamides could be mediated by rRNA methyltransferase, which modifies RNA in the drug-binding site [46] and chloramphenicol, florfenicol and clindamycin showed partially overlapped drug binding sites. Therefore, the use of florfenicol can confer resistance to chloramphenicol and clindamycin [46,48].

The highest prevalence of MDR was seen in Streptococcus spp. (29.0%), followed by Enterococcus spp. (24.3%), CNS (16.4%), E. coli (13.5%) and S. aureus (2.1%). Among them, 10 isolates showed resistance to six antimicrobial classes. Although the use of antimicrobials in the dairy industry in Korea is strictly monitored and managed, the emergence of antimicrobial-resistant pathogens in milk is of concern, because antimicrobial-resistant genes and mobile genetic elements, such as transposons, may be disseminated nationwide and transferred horizontally through mastitis pathogens [44,49].

5. Conclusions

Although there were no significant differences among factories in regards of IBC and SCC, the prevalence of pathogens and the antimicrobial resistance of them showed significant differences among factories, which could be affected by the management programs of dairy factories and companies. To prevent the emergence of the mastitis pathogens and its antimicrobial resistant
properties, strong monitoring and prevention programs of mastitis pathogens should be implemented among commercial dairy operations.

**Author Contributions:** Conceptualization, M.-J.Y. and S.Y.; methodology, M.-J.Y. and S.Y.; software, S.Y.; validation, S.Y. and Y.J.L.; formal analysis, S.Y. and Y.J.L.; investigation, M.-J.Y. and S.Y.; resources, M.-J.Y.; data curation, M.-J.Y. and S.Y.; writing—original draft preparation, M.-J.Y. and S.Y.; writing—review and editing, S.Y. and Y.J.L.; visualization, S.Y.; supervision, Y.J.L.; project administration, Y.J.L.; funding acquisition, Y.J.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Korea Research Fellowship program funded by the Ministry of Science and ICT through the National Research Foundation of Korea (2019H1D3A1A01102811).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Schwarz, D.; Dieterbeck, U.S.; Failing, K.; König, S.; Brügemann, K.; Zschöck, M.; Wolter, W.; Czerny, C.P. Somatic cell counts and bacteriological status in quarter foremilk samples of cows in Hesse, Germany—A longitudinal study. *J. Dairy Sci.* 2010, 93, 5716–5728, doi:10.3168/jds.2010-3223.

2. Berry, D.P.; Brien, B.O.; Callaghan, E.J.O.; Sullivan, K.O.; Meaney, W.J. Temporal Trends in Bulk Tank Somatic Cell Count and Total Bacterial Count in Irish Dairy Herds During the Past Decade. *J. Dairy Sci.* 2006, 89, 4083–4093, doi:10.3168/jds.S0022-0291(06)72453-5.

3. Cicconi-Hogan, K.M.; Gamroth, M.; Richert, R.; Ruegg, P.L.; Stiglbauer, K.E.; Schukken, Y.H. Associations of risk factors with somatic cell count in bulk milk on organic and conventional dairy farms in the United States. *J. Dairy Sci.* 2013, 96, 3689–3702, doi:10.3168/jds.2012-6271.

4. Cameron, M.; Keefe, G.P.; Roy, J.; Stryhn, H.; Dohoo, I.R.; Mckenna, S.L. Evaluation of selective dry cow treatment following on-farm culture: Milk yield and somatic cell count in the subsequent lactation. *J. Dairy Sci.* 2015, 98, 2427–2436, doi:10.3168/jds.2014-8876.

5. Syring, C.; Boss, R.; Reist, M.; Bodmer, M.; Hummerjohann, J.; Gehrig, P.; Graber, H.U. Bovine mastitis: The diagnostic properties of a PCR-based assay to monitor the *Staphylococcus aureus* genotype B status of a herd, using bulk tank milk. *J. Dairy Sci.* 2012, 95, 3674–3682, doi:10.3168/jds.2011-4968.

6. Riekerink, R.G.M.O.; Barkema, H.W.; Scholl, D.T.; Poole, D.E.; Kelton, D.F. Management practices associated with the bulk-milk prevalence of *Staphylococcus aureus* in Canadian dairy farms. *Prev. Vet. Med.* 2010, 97, 20–28, doi:10.1016/j.prevetmed.2010.07.002.

7. Bi, Y.; Wang, Y.J.; Qin, Y.; Vallverdú, R.G.; García, J.M.; Sun, W.; Li, S.; Cao, Z. Prevalence of Bovine Mastitis Pathogens in Bulk Tank Milk in China. *PLoS ONE* 2016, 11, e0155621, doi:10.1371/journal.pone.0155621.

8. Lopes Júnior, J.E.F.; Lange, C.C.; Brito, M.A.V.P.; Santos, F.R.; Silva, M.A.S.; de Moraes, L.C.D.; de Souza, G.N. Relationship between total bacteria counts and somatic cell counts from mammary quarters infected by mastitis pathogens. *Ciência Rural* 2012, 42, 691–696, doi:10.1590/S0103-84782012000400019.

9. Gillespie, B.E.; Lewis, M.J.; Boonyayatra, S.; Maxwell, M.L.; Saxton, A.; Oliver, S.P.; Almeida, R.A. Short communication: Evaluation of bulk tank milk microbiological quality of nine dairy farms in Tennessee. *J. Dairy Sci.* 2012, 95, 4275–4279, doi:10.3168/jds.2011-4881.

10. Ministry of Food and Drug Safety (MFDS). *Livestock Products Sanitary Control Act*; Ministry of Food and Drug Safety: Cheongju, Korea, 2017.

11. Rysanek, D.; Zouharova, M.; Babak, V. Monitoring major mastitis pathogens at the population level based on examination of bulk tank milk samples. *J. Dairy Res.* 2009, 76, 117–123, doi:10.1017/S0022029908003816.

12. Nam, H.-M.; Lee, A.; Jung, S.; Kim, M.; Jang, G.; Wee, S.-H.; Lim, S.-K. Antimicrobial Susceptibility of *Staphylococcus aureus* and Characterization of Methicillin-Resistant *Staphylococcus aureus* Isolated from Bovine Mastitis in Korea. *Foodborne Pathog. Dis.* 2011, 8, 231–238, doi:10.1089/fpd.2010.0661.

13. Cheng, J.; Qu, W.; Barbeka, H.W.; Nobrega, D.B.; Gao, J.; Liu, G.; Buck, J.; De; Kastelic, J.P.; Sun, H.; Han, B. Antimicrobial resistance profiles of 5 common bovine mastitis pathogens in large Chinese dairy herds. *J. Dairy Sci.* 2019, 102, 2416–2426, doi:10.3168/jds.2018-15135.

14. Burgos, J.M.; Ellington, B.A.; Varela, M.F. Presence of Multidrug Resistant Enteric Bacteria in Dairy Farm Topsoil. *J. Dairy Sci.* 2008, 88, 1391–1398, doi:10.3168/jds.S0022-0302(05)72806-X.
Animals 2020, 10, 1562

15. Ministry of Food and Drug Safety (MFDS). Processing Standards and Ingredient Specifications for Livestock Products; Ministry of Food and Drug Safety: Cheongju, Korea, 2018.

16. Candrian, U.; Furrer, B.; Höfelein, C.; Meyer, R.; Jermini, M.; Lüthy, J. Detection of Escherichia coli and identification of enterotoxigenic strains by primer-directed enzymatic amplification of specific DNA sequences. Int. J. Food Microbiol. 1991, 12, 339–351, doi:10.1016/0168-1605(91)90148-I.

17. Dutka-Malen, S.; Evers, S.; Courvalin, P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 1995, 33, 1434, doi:10.1128/JCM.33.5.1434-1434.1995.

18. Kim, C.H.; Khan, M.; Morin, D.E.; Hurley, W.L.; Tripathy, D.N.; Kehrl, M.; Olouoch, A.O.; Kakoma, I. Optimization of the PCR for detection of Staphylococcus aureus nuc gene in bovine milk. J. Dairy Sci. 2001, 84, 74–83, doi:10.3168/jds.S0022-0302(01)74454-2.

19. Lee, K.; Lee, J.; Wang, S.; Liu, L.; Lee, M.; Chuang, S.; Shy, Y.; Chang, C.; Wu, M.; Chi, C. Development of a novel biochip for rapid multiplex detection of seven mastitis-causing pathogens in bovine milk samples. J. Vet. Diagn. Invest. 2008, 20, 463–471.

20. Clinical and Laboratory Standards Institute (CLSI), M100 Performance Standards for Antimicrobial Susceptibility Testing; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2019.

21. Pourmand, M.R.; Hassanzadeh, S.; Mashhadi, R.; Askari, E. Comparison of four diagnostic methods for detection of methicillin resistant Staphylococcus aureus. Iran. J. Microbiol. 2014, 6, 341–344.

22. Magiorakos, A.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljeqvist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2011, 18, 268–281, doi:10.1111/j.1469-0691.2011.03570.x.

23. Banos, G.; Wall, E.; Coffey, M.P.; Bagnall, A.; Gillespie, S.; Russell, G.C.; Mcneilly, T.N. Identification of Immune Traits Correlated with Dairy Cow Health, Reproduction and Productivity. PLoS ONE 2013, 8, e65766, doi:10.1371/journal.pone.0065766.

24. Dufour, S.; Fréchette, A.; Barkema, H.W.; Mussell, A.; Scholl, D.T. Invited review: Effect of udder health management practices on herd somatic cell count. J. Dairy Sci. 2011, 94, 563–579, doi:10.3168/jds.2010-3715.

25. Korea Agro-Fisheries & Food Trade Corporation Food Information Statistics System (ATFIS) Available online: https://www.atfis.or.kr/ (accessed on 1 August, 2020).

26. Kandasamy, S.; Park, W.S.; Yoo, J.; Yun, J.; Kang, H.B.; Seol, K.-H.; Oh, M.-H.; Ham, J.S. Characterisation of fungal contamination sources for use in quality management of cheese production farms in Korea. Asian-Aust. J. Anim. Sci. 2020, 33, 1002–1011, doi:10.5713/ajas.19.0553.

27. Goldberg, J.I.; Wildman, E.E.; Pankey, J.W.; Kunkel, J.R.; Howard, D.B.; Murphy, B.M. The Influence of Intensively Managed Rotational Grazing, Traditional Continuous Grazing, and Confinement Housing on Bulk Tank Milk Quality and Udder Health. J. Dairy Sci. 1992, 75, 96–104, doi:10.3168/jds.1992-7743-1.

28. Jayarao, B.M.; Pillai, S.R.; Sawant, A.A.; Wolfgang, D.R.; Hegde, N. V Guidelines for Monitoring Bulk Tank Milk Somatic Cell and Bacterial Counts. J. Dairy Sci. 2004, 87, 3561–3573, doi:10.3168/jds.S0022-0302(04)73493-1.

29. Marshall, J.C.; Soboleva, T.K.; Jamieson, P.; French, N.P. Estimating Bacterial Pathogen Levels in New Zealand Bulk Tank Milk. J. Food Prot. 2016, 79, 771–780, doi:10.4315/0362-028X.JFP-15-230.

30. Park, Y.K.; Koo, H.C.; Kim, S.H.; Hwang, S.Y.; Jung, W.K.; Kim, J.M.; Shin, S.; Kim, R.T.; Park, Y.H. The Analysis of Milk Components and Pathogenic Bacteria Isolated from Bovine Raw Milk in Korea. J. Dairy Sci. 2007, 90, 5405–5414, doi:10.3168/jds.2007-0282.

31. Petzer, I.-M.; Karzis, J.; Donkin, E.F.; Webb, E.C.; Etter, E.M.C. Validity of somatic cell count as indicator of pathogen-specific intramammary infections. J. S. Afr. Vet. Assoc. 2017, 88, 1–10, doi:10.4102/jsava.v88i0.

32. Fenlon, D.R.; Logue, D.N.; Gunn, J.; Wilson, J. A study of mastitis bacteria and herd management practices to identify their relationship to high somatic cell counts in bulk tank milk. Br. Vet. J. 1995, 151, 17–25, doi:10.1016/s0007-1935(05)80059-4.

33. Koop, G.; Dik, N.; Nielen, M.; Lipman, L.J.A. Short communication: Repeatability of differential goat bulk milk culture and associations with somatic cell count, total bacterial count, and standard plate count. J. Dairy Sci. 2010, 93, 2569–2573, doi:10.3168/jds.2009-2705.
34. Sears, P.M.; Smith, B.S.; English, P.B.; Herer, P.S.; Gonzalez, R.N. Shedding Pattern of Staphylococcus aureus from Bovine Intramammary Infections. *J. Dairy Sci.* 1990, 73, 2785–2789, doi:10.3168/jds.S0022-0302(90)78964-3.

35. Sampimon, O.; Borne, B.H.P.; Van Den; Santman-berends, I.; Barkema, H.W.; Lam, T. Effect of coagulase-negative staphylococci on somatic cell count in Dutch dairy herds. *J. Dairy Res.* 2010, 77, 318–324, doi:10.1017/S0022029910000191.

36. Zadoks, R.; Fitzpatrick, J. Changing trends in mastitis. *Ir. Vet. J.* 2009, 62, 59–70, doi:10.1186/2046-0481-62-5-S59.

37. Nam, H.M.; Lim, S.K.; Moon, J.S.; Kang, H.M.; Kim, J.M.; Jang, K.C.; Kim, J.M.; Kang, M.I.; Joo, Y.S.; Jung, S.C. Antimicrobial Resistance of Enterococci Isolated from Mastitic Bovine Milk Samples in Korea. *Zoonoses Public Health* 2010, 57, e59–e64, doi:10.1111/j.1863-2378.2009.01307.x.

38. Nam, H.; Lim, S.; Kang, H.; Kim, J.; Moon, J.; Jang, K.; Joo, Y.; Kang, M.; Jung, S. Antimicrobial resistance of streptococci isolated from mastitic bovine milk samples in Korea. *J. Vet. Diagn. Invest.* 2009, 701, 698–701, doi:10.1177/104063870902100517.

39. Kim, S.-J.; Moon, D.C.; Park, S.-C.; Kang, H.Y.; Na, S.H.; Lim, S.-K. Antimicrobial resistance and genetic characterization of coagulase- negative staphylococci from bovine mastitis milk samples in Korea. *J. Dairy Sci.* 2019, 102, 11439–11448, doi:10.3168/jds.2019-17028.

40. National Institute of Food and Drug Safety Evaluation (NIFDS) *National Antimicrobial Resistance Surveillance on the Domestic and Imported Meat and Fishery Products;* National Institute of Food and Drug Safety Evaluation: Cheongju, Korea, 2019.

41. Caierao, J.; Musskopf, M.; Superti, S.; Roesch, E.; Dias, C.G.; D’Azevedo, P.A. Evaluation of phenotypic methods for methicillin resistance characterization in coagulase-negative staphylococci (CNS). *J. Med. Microbiol.* 2004, 53, 1195–1199, doi:10.1099/jmm.0.45697-0.

42. Jung, W.K.; Lim, J.Y.; Kwon, N.H.; Kim, J.M.; Hong, S.K.; Koo, H.C.; Kim, S.H.; Park, Y.H. Vancomycin-resistant enterococci from animal sources in Korea. *Int. J. Food Microbiol.* 2007, 113, 102–107, doi:10.1016/j.ijfoodmicro.2006.07.023.

43. Denamiel, G.; Llorente, P.; Carabella, M.; Rebuelto, M.; Gentilini, E. Anti-microbial Susceptibility of Streptococcus spp. Isolated from Bovine Mastitis in Argentina. *J. Vet. Med.* 2005, 52, 125–128, doi:10.1111/j.1439-0450.2005.00830.x.

44. Tark, D.; Moon, D.C.; Kang, H.Y.; Kim, S.; Nam, H.; Lee, H. Antimicrobial susceptibility and characterization of extended-spectrum β-lactamases in Escherichia coli isolated from bovine mastitic milk in South Korea from 2012 to 2015. *J. Dairy Sci.* 2017, 100, 3463–3469, doi:10.3168/jds.2016-12276.

45. Nam, H.M.; Lim, S.K.; Kang, H.M.; Kim, J.M.; Moon, J.S.; Jang, K.C.; Kim, J.M.; Joo, Y.S.; Jung, S.C. Prevalence and antimicrobial susceptibility of gram-negative bacteria isolated from bovine mastitis between 2003 and 2008 in Korea. *J. Dairy Sci.* 2009, 92, 2020–2026, doi:10.3168/jds.2008-1739.

46. Kehrenberg, C.; Schwarz, S.; Jacobsen, L.; Hansen, L.H.; Vester, B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: Methylation of 23S ribosomal RNA at A2503. *Mol. Microbiol.* 2005, 57, 1064–1073, doi:10.1111/j.1365-2958.2005.04754.x.

47. White, D.G.; Hudson, C.; Maurer, J.J.; Ayers, S.; Zhao, S.; Lee, M.D.; Bolton, L.; Foley, T.; Sherwood, J. Characterization of Chloramphenicol and Florfenicol Resistance in Escherichia coli Associated with Bovine Diarrhea. *J. Clin. Microbiol.* 2000, 38, 4593–4598.

48. Liu, J.; Zhao, Z.; Avillan, J.J.; Call, D.R.; Davis, M.; Sischo, W.M.; Zhang, A. Dairy farm soil presents distinct microbiota and varied prevalence of antibiotic resistance across housing areas. *Environ. Pollut.* 2019, 254, 113058, doi:10.1016/j.envpol.2019.113058.

49. Gao, X.; Fan, C.; Zhang, Z.; Li, S.; Xu, C.; Zhao, Y.; Han, L.; Zhang, D.; Liu, M. Microbial Pathogenesis Enterococcal isolates from bovine subclinical and clinical mastitis: Antimicrobial resistance and integron-gene cassette distribution. *Microb. Pathogenes.* 2019, 129, 82–87, doi:10.1016/j.micpath.2019.01.031.